CAR-Treg cells designed to express HLA-A*02 CAR have been shown to induce immunosuppression of allograft-specific effector T cells and prevent graft-versus-host disease (GVHD) in preclinical models.1105,1106 Therefore, two phase I/II clinical trials of HLA-A2-CAR-Treg cells (TX200-TR101 and QEL-001) have been registered for organ transplantation (Table 5). This evidence concerns the gene HLA-A and graft versus host disease.